-
公开(公告)号：US20100015045A1
公开(公告)日：2010-01-21
申请号：US12504473
申请日：2009-07-16
IPC分类号： A61K51/00 , A61K39/395 , A61P35/04 , G01N33/574 , C12N5/00 , C12N5/02 , C07K16/00
CPC分类号： G01N33/574 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K16/3046 , C07K2317/56
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
摘要翻译： 本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物和血细胞结合。
-
公开(公告)号：US07485300B2
公开(公告)日：2009-02-03
申请号：US11709457
申请日：2007-02-22
申请人： David S. F. Young , Helen P. Findlay , Susan E. Hahn , Lisa M. Cechetto , Fortunata McConkey , Daad Sayegh
发明人： David S. F. Young , Helen P. Findlay , Susan E. Hahn , Lisa M. Cechetto , Fortunata McConkey , Daad Sayegh
IPC分类号： A61K39/00
CPC分类号： C07K16/30 , A61K38/21 , A61K47/6851 , A61K51/1045 , A61K2039/505
摘要： The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及使用新颖的筛选范例制备癌性疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。
-
公开(公告)号：US20080219919A1
公开(公告)日：2008-09-11
申请号：US11807887
申请日：2007-05-30
IPC分类号： A61K39/395 , A61K51/10 , G01N33/574 , C07K16/46 , C07K16/30 , A61K38/21 , A61P35/00
CPC分类号： G01N33/57449 , A61K47/6849 , A61K47/6897 , A61K51/1051 , A61K51/1063 , A61K51/1072 , A61K2039/505 , B82Y5/00 , C07K16/2884 , C07K2317/24 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/5082 , G01N33/574 , G01N33/57415 , G01N33/57419 , G01N33/57434 , G01N33/57438 , G01N2333/70585
摘要： This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
-
4.发明申请公开(公告)号：US20120201751A1
公开(公告)日：2012-08-09
申请号：US13310917
申请日：2011-12-05
申请人： David S. F. Young , Helen P. Findlay , Susan E. Hahn , Lisa M. Cechetto , Fortunata McConkey , Maximiliano Vasquez
发明人： David S. F. Young , Helen P. Findlay , Susan E. Hahn , Lisa M. Cechetto , Fortunata McConkey , Maximiliano Vasquez
IPC分类号： A61K39/395 , A61K51/10 , A61P35/00
CPC分类号： G01N33/57449 , A61K47/6849 , A61K47/6897 , A61K51/1051 , A61K51/1063 , A61K51/1072 , A61K2039/505 , B82Y5/00 , C07K16/2884 , C07K2317/24 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/5082 , G01N33/574 , G01N33/57415 , G01N33/57419 , G01N33/57434 , G01N33/57438 , G01N2333/70585
摘要： This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及癌性疾病（原发性肿瘤和肿瘤转移）的分期，诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及可选地与一种或多种CDMAB /化学治疗剂组合使用癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。
-
5.发明授权公开(公告)号：US08071072B2
公开(公告)日：2011-12-06
申请号：US11807887
申请日：2007-05-30
申请人： David S. F. Young , Helen P. Findlay , Susan E. Hahn , Lisa M. Cechetto , Fortunata McConkey , Maximiliano Vasquez
发明人： David S. F. Young , Helen P. Findlay , Susan E. Hahn , Lisa M. Cechetto , Fortunata McConkey , Maximiliano Vasquez
IPC分类号： A61K39/395 , A61K51/10 , A61P35/00 , C07K16/30 , C07K16/46 , G01N33/574
CPC分类号： G01N33/57449 , A61K47/6849 , A61K47/6897 , A61K51/1051 , A61K51/1063 , A61K51/1072 , A61K2039/505 , B82Y5/00 , C07K16/2884 , C07K2317/24 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/5082 , G01N33/574 , G01N33/57415 , G01N33/57419 , G01N33/57434 , G01N33/57438 , G01N2333/70585
摘要： This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及癌性疾病（原发性肿瘤和肿瘤转移）的分期，诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及可选地与一种或多种CDMAB /化学治疗剂组合使用癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。
-
6.发明申请公开(公告)号：US20080274049A1
公开(公告)日：2008-11-06
申请号：US12217279
申请日：2008-07-01
IPC分类号： A61K51/10 , C12N5/08 , A61K39/395 , G01N33/574 , A61P35/00 , C07K16/28 , A61K39/44
CPC分类号： C07K16/2884 , A61K47/6849 , A61K47/6897 , A61K49/0013 , A61K49/0058 , A61K2039/505 , B82Y5/00 , C07K2317/24 , C07K2317/56 , C07K2317/73 , G01N33/5082 , G01N33/574 , G01N33/57492 , G01N2333/70585
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。
-
7.发明申请公开(公告)号：US20080124327A1
公开(公告)日：2008-05-29
申请号：US11975897
申请日：2007-10-22
IPC分类号： A61K39/395 , G01N33/53 , C07K16/00 , A61P35/00
CPC分类号： G01N33/57492 , A61K47/6849 , A61K47/6897 , A61K49/0013 , A61K2039/505 , B82Y5/00 , C07K16/2884 , C07K2317/24 , C07K2317/56 , C07K2317/73 , C07K2317/75 , C07K2317/76 , G01N33/5082 , G01N33/574 , G01N2333/70585
摘要： This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
摘要翻译： 本发明涉及癌性疾病（原发性肿瘤和肿瘤转移）的分期，诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及可选地与一种或多种CDMAB /化学治疗剂组合使用癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。 抗癌抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血细胞结合。
-
8.发明授权公开(公告)号：US08017117B2
公开(公告)日：2011-09-13
申请号：US12217279
申请日：2008-07-01
IPC分类号： A61K39/395 , A61K38/44
CPC分类号： C07K16/2884 , A61K47/6849 , A61K47/6897 , A61K49/0013 , A61K49/0058 , A61K2039/505 , B82Y5/00 , C07K2317/24 , C07K2317/56 , C07K2317/73 , G01N33/5082 , G01N33/574 , G01N33/57492 , G01N2333/70585
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
摘要翻译： 本发明涉及癌症的诊断和治疗，特别涉及肿瘤细胞的细胞毒性的介导; 并且最特别地涉及使用任选与一种或多种化学治疗剂组合的癌性疾病修饰抗体（CDMAB）作为起始细胞毒性应答的手段。 本发明还涉及利用本发明的CDMAB的结合测定法。
-
公开(公告)号：US07947496B2
公开(公告)日：2011-05-24
申请号：US11364013
申请日：2006-02-28
CPC分类号： C07K16/2884 , A61K47/6849 , A61K47/6897 , A61K49/0013 , A61K49/0058 , A61K2039/505 , B82Y5/00 , C07K2317/24 , C07K2317/56 , C07K2317/73 , G01N33/5082 , G01N33/574 , G01N33/57492 , G01N2333/70585
摘要： This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.
-
公开(公告)号：US20080131429A1
公开(公告)日：2008-06-05
申请号：US11879676
申请日：2007-07-18
IPC分类号： A61K39/395 , G01N33/53 , C07K16/00
CPC分类号： G01N33/574 , C07K16/2884 , C07K2317/24 , G01N2333/70585
摘要： This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.
-
-
-
-
-
-
-
-
-
搜索结果
86 条记录 (耗时 0.042 秒)
